Description:

Enzacept (Enzalutamide 40 mg Capsules) is an androgen receptor inhibitor used in the treatment of prostate cancer. It is a novel hormonal therapy that blocks the action of androgens (male hormones), which fuel the growth of prostate cancer cells.
Enzalutamide is particularly effective in castration-resistant prostate cancer (CRPC) and metastatic hormone-sensitive prostate cancer (mHSPC).
Enzalutamide works by binding to the androgen receptor and inhibiting multiple steps in the androgen receptor signaling pathway:

• Prevents androgen binding
• Inhibits nuclear translocation of the androgen receptor
• Blocks DNA binding and transcription of androgen-responsive genes

This triple-action mechanism suppresses cancer cell proliferation and promotes cancer cell death.

Enzacept is indicated for:

• Metastatic castration-resistant prostate cancer (mCRPC)
• Non-metastatic castration-resistant prostate cancer (nmCRPC)
• Metastatic hormone-sensitive prostate cancer (mHSPC)